Silence Therapeutics stock soars 125% on Merck acquisition

Silence Therapeutics experienced a stock price surge of 125% following the announcement of its acquisition by Germany's Merck. The deal is valued at $1.3 billion, marking a significant transaction for both entities. This acquisition integrates Silence Therapeutics into the Merck portfolio, driving a massive increase in shareholder value as reported by Reuters. The financial markets reacted positively to the news, reflecting the strategic importance of the merger within the pharmaceutical and biotechnology sectors.